- BioPharm International-07-01-2002
- Volume 15
- Issue 7
Virus Inactivation in the 1990's ? and into the 21st Century. Part 1: Skin, Bone, and Cells
by Gail Sofer, BioReliance Viruses present dangers (and therefore challenges) to biopharmaceutical manufacturing processes. The virus inactivation method chosen depends on the virus and its surrounding medium. This survey article, organized by sample type, lists viral inactivation methods published during the past decade. Part 1 presents data for skin and bone and for cells that are not platelets or blood cells.
Articles in this issue
about 23 years ago
Facilitating Client Audits: The Contract Laboratory Perspectiveabout 23 years ago
Knowledge Management: The Four Pillars of Successabout 23 years ago
Inside Washington: One Hundred Years of Biotech Regulationabout 23 years ago
Guest Editorial: Supreme Court Rules on FestoNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.